Prescription Drugs: Price Disclosures in Advertisements
A house committee must act next: committee consideration.
While the bill has support from both parties and addresses high drug costs, it faces a long path through committees and potential pushback from the pharmaceutical industry.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
The disclosure requirement applies to drugs paid for under title XIX (Medicaid) as well as Medicare, so Medicaid enrollees who see drug ads would also see list prices. This could help some enrollees and their doctors weigh cheaper alternatives before starting an expensive brand-name drug.
“a prescription drug or biological product for which payment is available under title XVIII or XIX”
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Sens. Dick Durbin and Chuck Grassley reintroduced the Drug-price Transparency for Consumers (DTC) Act of 2025. The bill requires price disclosures in all ads for prescription drugs, aiming to empower patients and reduce spending on medications that often offer 'low therapeutic value.'
Industry analysts argue the DTC Act of 2025 is 'bad policy' because list prices do not reflect what insured patients actually pay. Critics suggest the bill is a tactic to discourage drug advertising by creating a false belief that many medications are unaffordable.
Sens. Durbin and Grassley sought unanimous consent to pass the DTC Act of 2025 on the Senate floor. Despite support from the Trump administration and HHS Secretary Robert F. Kennedy Jr., the request was blocked by a Republican colleague, stalling the measure.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
DTC Act of 2025
Analysis generated by AI. Always verify with official sources.